Peripheral T-Cell Lymphoma With Aberrant Expression of CD30, CD15, and CD20
- 10 November 2011
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (32) , e789-e791
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locusLaboratory Investigation, 2010
- Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecifiedLeukemia Research, 2009
- CD20+ T-cell LymphomaAmerican Journal of Surgical Pathology, 2008
- Rare expression of T-cell markers in classical Hodgkin's lymphomaLaboratory Investigation, 2005
- Peripheral T-Cell Lymphomas Expressing CD30 and CD15American Journal of Surgical Pathology, 2003
- Peripheral T-Cell Lymphoma with Aberrant Expression of CD79a and CD20: A Diagnostic PitfallLaboratory Investigation, 2001
- Immunoreactivity of B-Cell Markers (CD79a, L26) in Rare Cases of Extranodal Cytotoxic Peripheral T- (NK/T-) Cell LymphomasLaboratory Investigation, 2000
- Peripheral T-Cell Lymphoma With Reed-Sternberg-like Cells of B-Cell Phenotype and Genotype Associated With Epstein-Barr Virus InfectionAmerican Journal of Surgical Pathology, 1999